---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-240858"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:34:29.009288+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones

## Summary
- Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
- Additional up to $962M in development, regulatory, and sales-based milestones across five indications.
- Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.
- Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads.

## SEC filing metadata
- accession: 0001193125-25-240858
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/0001193125-25-240858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/dnth-20251016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-240858
- JSON: https://secwatch.observer/filing/0001193125-25-240858.json
- Plain text: https://secwatch.observer/filing/0001193125-25-240858.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.